Cite
HARVARD Citation
Vallejo-Vaz, A. et al. (2020). Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab. European journal of preventive cardiology. pp. 1663-1674. [Online].